WO2021129616A1 - Combinaison pharmaceutique d'anticorps anti-pd-1 et d'inhibiteur d'histone désacétylase, son utilisation et son procédé d'utilisation - Google Patents

Combinaison pharmaceutique d'anticorps anti-pd-1 et d'inhibiteur d'histone désacétylase, son utilisation et son procédé d'utilisation Download PDF

Info

Publication number
WO2021129616A1
WO2021129616A1 PCT/CN2020/138343 CN2020138343W WO2021129616A1 WO 2021129616 A1 WO2021129616 A1 WO 2021129616A1 CN 2020138343 W CN2020138343 W CN 2020138343W WO 2021129616 A1 WO2021129616 A1 WO 2021129616A1
Authority
WO
WIPO (PCT)
Prior art keywords
carbon atoms
group
antibody
cancer
hdac inhibitor
Prior art date
Application number
PCT/CN2020/138343
Other languages
English (en)
Chinese (zh)
Inventor
黄慧强
高岩
唐晓义
鲁先平
付鑫
俞德超
Original Assignee
信达生物制药(苏州)有限公司
深圳微芯生物科技股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 信达生物制药(苏州)有限公司, 深圳微芯生物科技股份有限公司 filed Critical 信达生物制药(苏州)有限公司
Publication of WO2021129616A1 publication Critical patent/WO2021129616A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention relates to a pharmaceutical combination of an anti-PD-1 antibody or an antigen binding fragment thereof and a histone deacetylase inhibitor, which is used for the prevention or treatment of cancer, especially extranodal NK/T cell lymphoma.
  • the present invention also relates to the use of the drug combination in the preparation of a drug for preventing or treating cancer, especially extranodal NK/T cell lymphoma, and a method for applying the drug combination to prevent or treat cancer, especially extranodal NK/T cell lymphoma .
  • Extranodal NK/T-cell lymphoma, nasal type is a rare subtype of non-Hodgkin’s lymphoma, in all non-Hodgkin’s lymphoma subtypes in my country Among them, it accounts for up to 6%. It is highly invasive, and the prognosis of patients with newly-treated late stage and refractory relapsed patients is poor. ENKTL mainly occurs in the nasal cavity, followed by the skin and gastrointestinal tract. The main pathological manifestations of this disease are vascular invasion and tissue destruction. Specific markers and specific genetic changes on the surface of ENKTL cells can also help diagnose the disease.
  • ENKTL is closely related to Epstein-Barr virus (EBV) infection, and the level of EBV-DNA has important significance for its prognosis and auxiliary diagnosis.
  • EBV Epstein-Barr virus
  • the treatment of ENKTL lacks prospective, randomized, controlled clinical research, and there is no standard treatment method.
  • Its main treatment methods include radiotherapy, chemotherapy and hematopoietic stem cell transplantation.
  • radiotherapy ⁇ L-asparaginase-based chemotherapy combined treatment mode is adopted, and the 5-year overall survival (OS) of the patient can exceed 80%.
  • NCCN National Comprehensive Cancer Network
  • the ORR and CRR were 81% and 66%, respectively, the 5-year OS rate was 50%, and the 4-year progression-free survival (PFS) rate was 64%; 57 patients had grade 3/4 neutropenia , 36 patients had grade 3/4 thrombocytopenia, and 15 patients had nephrotoxicity. Among them, 5 patients died of treatment-related sepsis; 1 patient died of acute renal failure caused by high-dose methotrexate [2].
  • the GELA and GOELAMS collaborative group reported the results of AspaMetDex (L-asparaginase, high-dose methotrexate, and dexamethasone) in the treatment of 19 patients with refractory and relapsed ENKTL.
  • the ORR and CRR were 78% and 61%, respectively.
  • the median OS was 1 year, and the median duration of response was 12 months.
  • the main adverse events were hepatitis, cytopenias and allergies, but there were still 5 patients with high-dose methotrexate-related transient renal insufficiency, and grade 3/4 agranular fever [3].
  • the P-Gemox regimen is safer than SMILE and AspaMetDex regimens, and the survival of newly-treated stage I/II patients is satisfactory, but the survival of newly-treated stage III/IV and refractory relapsed patients is still poor [4].
  • domestic and foreign researchers have tried to further improve the prognosis of ENKTL in the late stage and refractory relapsed ENKTL through different cytotoxic drug combinations, but they have not achieved a breakthrough, and traditional cytotoxic drug treatment has encountered a bottleneck in curative effect. Therefore, how to improve the survival of newly treated stage III/IV and refractory relapsed patients is the direction of the next treatment.
  • Histone deacytelase is involved in the biological processes of a variety of tumors. When tumors occur, their activity is significantly increased, which makes the histones in the nucleosomes in a state of hypoacetylation, leading to tumor suppressor genes. Transcription activity is inhibited, and the abnormal expression of a variety of genes that regulate cell proliferation and cell cycle causes malignant transformation of cells [5].
  • HDAC inhibitors are a new type of small-molecule targeted drugs that play an anti-tumor effect by regulating epigenetics. By blocking the deacetylation of HDAC, DNA maintains transcriptional activity and causes changes in multiple downstream signaling pathways. , Can cause tumor cell apoptosis, induce cell differentiation and inhibit angiogenesis [5-7].
  • Chidamide is a subtype-selective oral HDAC inhibitor. Its main target is type I and type II HDAC. It has been approved for the treatment of refractory and relapsed peripheral T-cell lymphoma in my country. In the pivotal phase II clinical trial (registered clinical trial), a total of 83 patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) were enrolled, and all received 30 mg/time, twice/week of chidamide Treatment until the disease progresses or untolerable adverse reactions occur.
  • PTCL peripheral T-cell lymphoma
  • ORR The main efficacy index is ORR.
  • the ORR of chidamide was only 25%, and the CRR was 6% [8].
  • DCR disease control rate
  • Chidamide may be an effective drug for potential treatment of ENKTL, its efficacy still has great limitations.
  • Programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) axis is a powerful signaling pathway to inhibit immune activation, and it is also a tumor to achieve immune escape One of the important mechanisms [10,11].
  • Tumor infiltrating lymphocytes highly express PD-1. These PD-1 combine with PD-L1 on the surface of tumor cells or immune cells to inhibit the initial activation of T cells, and inhibit the production and function of effector T cells (including cytokine production and Cytotoxicity) [12,13].
  • Cinda Biopharmaceuticals (Suzhou) Co., Ltd. a well-known national medical center in the United Nations, carried out a multi-center, single-arm Phase II clinical study (ORIENT-4) of Sintilimab as a single agent in refractory and relapsed ENKTL in 2017. , The patient received Sintilizumab (200mg IV Q3W) monotherapy until the disease progressed, died, the toxicity was intolerable or the study was withdrawn. In the study, PET-CT and enhanced CT/MRI were used to evaluate tumor response. The main study endpoint is ORR based on the LUGANO 2014 efficacy evaluation criteria for malignant lymphoma.
  • AE adverse events
  • the present invention provides a pharmaceutical combination comprising a PD-1 antibody or an antigen-binding fragment thereof and an HDAC inhibitor,
  • the anti-PD-1 antibody contains 6 CDRs, and LCDR1, LCDR2, and LCDR3 are composed of the amino acid sequences RASQGISSWLA (SEQ ID NO: 9), SAASSLQS (SEQ ID NO: 10) and QQANHLPFT (SEQ ID NO: 11), respectively, and Wherein HCDR1, HCDR2 and HCDR3 are respectively composed of amino acid sequences KASGGTFSSYAIS (SEQ ID NO: 2), LIIPMFDTAGYAQKFQG (SEQ ID NO: 5) and ARAEHSSTGTFDY (SEQ ID NO: 8); or
  • the anti-PD-1 antibody is selected from Sintilimab, Pembrolizumab, Nivolumab, Teriplizumab and Carrelizumab;
  • HDAC inhibitor is selected from the following compounds of formula I or pharmaceutically acceptable salts thereof:
  • A is a benzene ring or heterocyclic ring, which can contain 1 to 4 substituents, and its substituents can be halogen, amino, hydroxyl, nitro, cyano, alkyl with 1 to 4 carbon atoms, 1 to 4 Carbon atom alkoxy group, 1 to 4 carbon atom aminoalkyl group, 1 to 4 carbon atom alkylamino group, 2 to 4 carbon atom acyl group, 2 to 4 carbon atom acyl group, 1 to 4 A thioalkyl group of 1 to 4 carbon atoms, a perfluoroalkyl group of 1 to 4 carbon atoms, a perfluoroalkoxy group of 1 to 4 carbon atoms, a carboxyl group of 1 to 4 carbon atoms, and a perfluoroalkyl group of 1 to 4 carbon atoms Alkoxycarbonyl, phenyl or heterocyclic substituents;
  • B is a benzene ring or heterocyclic ring, which can contain 1 to 3 substituents, and its substituents can be halogen, amino, hydroxyl, nitro, cyano, alkyl with 1 to 4 carbon atoms, and 1 to 4 carbon atoms Alkoxy, aminoalkyl of 1 to 4 carbon atoms, alkylamino of 1 to 4 carbon atoms, acyl of 2 to 4 carbon atoms, acylamino of 2 to 4 carbon atoms, 1 to 4 carbons Atom thioalkyl group, 1 to 4 carbon atom perfluoroalkyl group, 1 to 4 carbon atom perfluoroalkoxy group, 1 to 4 carbon atom carboxyl group, 1 to 4 carbon atom alkoxy group Carbonyl, phenyl or heterocyclic substituents:
  • Z is a covalent bond, an alkylene of 1 to 4 carbon atoms, or a linear structure or a ring containing -O-, -S-, -NH, -CO-, -CS-, -SO-, -SO 2- Structure or a combination of linear structure and cyclic structure;
  • Y is a linear structure, a cyclic structure or a combination of a linear structure and a cyclic structure containing -CO-, -CS-, -SO-, -SO 2 -, wherein the center point (W1) of ring A and the center of ring B
  • the distance between the point (W2) and the O atom or S atom (W3) contained in Y as the hydrogen bond acceptor satisfies the following conditions: The better distance between them is
  • R 1 and R 2 are respectively hydrogen or an alkyl group containing 1 to 4 carbon atoms, and R 1 and R 2 can also form a covalent bond together;
  • R 3 is hydrogen or an alkyl group containing 1 to 4 carbon atoms
  • R 4 is hydrogen, halogen, amino, hydroxyl, nitro, cyano, alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, aminoalkyl of 1 to 4 carbon atoms, 1 Alkylamino of to 4 carbon atoms, acyl of 2 to 4 carbon atoms, amido of 2 to 4 carbon atoms, thioalkyl of 1 to 4 carbon atoms, perfluoroalkane of 1 to 4 carbon atoms Group, perfluoroalkoxy group of 1 to 4 carbon atoms, carboxyl group of 1 to 4 carbon atoms, alkoxycarbonyl group of 1 to 4 carbon atoms;
  • One of X 1 , X 2 , X 3 , and X 4 is halogen, amino, hydroxyl, nitro, cyano, alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, 1 to Aminoalkyl groups of 4 carbon atoms, alkylamino groups of 1 to 4 carbon atoms, acyl groups of 2 to 4 carbon atoms, acylamino groups of 2 to 4 carbon atoms, thioalkyl groups of 1 to 4 carbon atoms, Perfluoroalkyl groups of 1 to 4 carbon atoms, perfluoroalkoxy groups of 1 to 4 carbon atoms, carboxyl groups of 1 to 4 carbon atoms, alkoxycarbonyl groups of 1 to 4 carbon atoms; the rest are hydrogen , Halogen, amino, hydroxyl, nitro, cyano, alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, aminoalkyl of 1 to
  • HDAC inhibitor is selected from Vorinostat, Romidepsin, Belinostat, Panobinostat, Chidamide, Entinol Special (Entinostat) and Mocetinostat (MGCD0103).
  • the anti-PD-1 antibody comprises a heavy chain variable region VH and a light chain variable region VL, wherein the heavy chain variable region comprises the sequence of SEQ ID NO: 13 or has at least 90% of the sequence of SEQ ID NO: 13 , 95%, 98%, or 99% identical sequences, and/or the light chain variable region comprising the sequence of SEQ ID NO: 15 or a sequence having at least 90%, 95%, 98% or 99% identity therewith;
  • the anti-PD-1 antibody comprises SEQ ID NO: 17 or a heavy chain sequence with at least 90%, 95%, 98% or 99% identity and/or SEQ ID NO: 22 or has A light chain sequence that is at least 90%, 95%, 98%, or 99% identical.
  • the anti-PD-1 antibody or antigen-binding fragment thereof is selected from Sintilimab, Pembrolizumab, Nivolumab, and Trepre Lizumab and Carrelizumab; preferably, the anti-PD-1 antibody is Sintilizumab.
  • the HDAC inhibitor is selected from the group consisting of Vorinostat, Romidepsin, Belinostat, Panobinostat, and Panobinostat. Chidamide, Entinostat and Mocetinostat (MGCD0103) or a pharmaceutically acceptable salt thereof, more preferably, the HDAC inhibitor is Chidamide.
  • the drug combination is used to prevent or treat cancer, preferably non-Hodgkin's lymphoma, more preferably extranodal NK/T cell lymphoma, most preferably late or refractory extranodal NK/T Cell lymphoma.
  • the anti-PD-1 antibody or antigen-binding fragment thereof in the pharmaceutical combination is in the form of a dosage unit of 100-300 mg, preferably 100 mg, 150 mg, 200 mg, 250 mg or 300 mg, more preferably 200 mg, Preferably it is a parenteral, more preferably an intravenous administration form; and/or
  • the HDAC inhibitor is in the form of a dosage unit of 10 to 50 mg, preferably 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg or 50 mg, preferably in a dosage form for oral administration.
  • the single administration dose of the anti-PD-1 antibody or antigen-binding fragment thereof is selected from 100-300 mg, such as 100 mg, 150 mg, 200 mg, 250 mg or 300 mg, preferably once every two to four weeks, preferably It is administered by intravenous infusion.
  • the anti-PD-1 antibody or antigen-binding fragment thereof is intravenously infused once every three weeks, and the single infusion dose is 200 mg.
  • the single administration dose of the HDAC inhibitor is selected from 10mg-50mg, preferably 1-4 times per week, preferably by oral administration;
  • the oral dose of the HDAC inhibitor is selected from 20 mg, 25 mg and 30 mg.
  • the HDAC inhibitor is taken orally twice a week, and each oral dose is 30 mg.
  • the anti-PD-1 antibody or antigen-binding fragment thereof and the HDAC inhibitor are administered separately, simultaneously or sequentially.
  • the anti-PD-1 antibody or its binding fragment can be continuously administered for treatment.
  • the present invention provides the use of the drug combination of the anti-PD-1 antibody or its antigen-binding fragment and HDAC inhibitor as defined in the first aspect in the preparation of a drug for the prevention or treatment of cancer, and the cancer is preferably selected From non-Hodgkin's lymphoma, extranodal NK/T cell lymphoma is more preferred, and extranodal NK/T cell lymphoma that is advanced or refractory to relapse is most preferred.
  • the present invention provides a method for preventing or treating cancer, the method comprising administering to a patient in need a therapeutically effective amount of the anti-PD-1 antibody or antigen-binding fragment thereof defined in the first aspect and HDAC inhibition
  • the cancer is preferably selected from non-Hodgkin’s lymphoma, more preferably extranodal NK/T cell lymphoma, most preferably advanced or refractory and relapsed extranodal NK/T cell lymphoma.
  • the present invention also provides a single drug dosage unit, which includes a therapeutically effective amount of the drug combination of the anti-PD-1 antibody or antigen-binding fragment thereof as defined in the first aspect and an HDAC inhibitor.
  • the present invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically effective amount of the anti-PD-1 antibody or antigen-binding fragment thereof as defined in the first aspect and a pharmaceutical combination of an HDAC inhibitor and pharmaceutically acceptable excipients Agent.
  • the present invention also provides a kit of medicines comprising a therapeutically effective amount of the anti-PD-1 antibody or antigen-binding fragment thereof defined in the first aspect and a drug combination of an HDAC inhibitor.
  • the present invention also provides the use of the above-mentioned single drug dosage unit, pharmaceutical composition or kit in the preparation of a drug for preventing or treating cancer.
  • the cancer is preferably selected from non-Hodgkin’s lymphoma, more preferably nodal. Extranodal NK/T cell lymphoma, most preferably advanced or refractory and relapsed extranodal NK/T cell lymphoma.
  • the term “comprising” or “including” means including the stated elements, integers or steps, but does not exclude any other elements, integers or steps.
  • the term “comprises” or “includes” when used, unless otherwise specified, it also encompasses the situation consisting of the stated elements, integers or steps.
  • an antibody variable region that "comprises” a specific sequence when referring to an antibody variable region that "comprises” a specific sequence, it is also intended to encompass the antibody variable region composed of the specific sequence.
  • antibody refers to a polypeptide comprising at least a light chain or heavy chain immunoglobulin variable region, which specifically recognizes and binds to an antigen.
  • the term encompasses various antibody structures, including, but not limited to, monoclonal antibodies, polyclonal antibodies, single-chain or multi-chain antibodies, monospecific or multispecific antibodies (such as bispecific antibodies), fully human antibodies, or Chimeric antibodies or humanized antibodies, full-length antibodies, and antibody fragments, as long as they exhibit the desired antigen-binding activity.
  • antigen-binding fragment of an antibody (which can be used interchangeably with “antibody fragment” and “antigen-binding portion” herein) refers to a molecule that is not an intact antibody, which includes the intact antibody used to bind the intact antibody. Part of the antigen. As understood by those skilled in the art, the antigen-binding portion of an antibody usually contains amino acid residues from the "complementarity determining region" or "CDR".
  • the antigen-binding fragment can be prepared by recombinant DNA technology, or by enzymatic or chemical cleavage of the intact antibody.
  • Antigen-binding fragments include but are not limited to Fab, scFab, Fab', F(ab')2, Fab'-SH, Fv, single-chain Fv, double-chain antibody (diabody), triabody (triabody), four-chain antibody ( tetrabody), minibody (minibody), single domain antibody (sdAb).
  • prevention includes the suppression or delay of the occurrence or frequency of the occurrence or occurrence of a disease or disorder or its symptoms, and it generally refers to the administration of drugs before the occurrence or occurrence of the symptoms or symptoms, especially before the occurrence of the symptoms or symptoms in individuals at risk.
  • treatment refers to the slowing, prevention or reversal of the progression of a subject's cancer (for example, extranodal NK/T cell lymphoma) as evidenced by the reduction or elimination of clinical or diagnostic symptoms of the disease. Treatment may include, for example, reducing the severity of symptoms, the number of symptoms, or the frequency of recurrence, for example, tumor growth inhibition, tumor growth arrest, or regression of existing tumors.
  • single drug dosage unit refers to a single drug dosage form administered to a patient at the time of the dosing schedule, including injections, tablets, and freeze-dried powders.
  • drug combination refers to a non-fixed combination product or a fixed combination product, such as a kit.
  • non-fixed combination means that the active ingredients (for example, (i) anti-PD-1 antibodies or antigen-binding fragments thereof, and (ii) HDAC inhibitors as separate entities are simultaneously, without a specific time limit, or in the same or different
  • the two agents are administered to the patient sequentially at intervals of time, wherein such administration provides prophylactic or therapeutically effective levels of the two active agents in the patient.
  • the anti-PD-1 antibody molecule and HDAC used in the drug combination The two molecules of the inhibitor are administered at a level not exceeding the level when they are used alone.
  • the term "fixed combination" means that the two active agents are administered to the patient simultaneously in the form of a single entity.
  • the dosage and/or of the two active agents are preferred.
  • the time interval is selected so that the combined use of each part can produce an effect greater than that achieved by using any single component in the treatment of diseases or conditions.
  • Each component can be in the form of a separate preparation, and the preparation form can be the same or different.
  • the term “therapeutically effective amount” as used herein refers to the combined effect that triggers the desired biological or medical response when administered in combination, that is, one or more cancers that are inhibited or improved include extranodal NK/T cell lymph
  • the combined dose for the clinical or diagnostic symptoms of tumors when referring to combination therapy, the term “therapeutically effective amount” as used herein refers to antibodies that produce a therapeutically effective and/or synergistic combination when administered together (sequentially or simultaneously) on the same day or on different days in the treatment cycle. Dosage and dosage of chemotherapy drugs.
  • the amount of individual antibodies and/or chemicals may or may not be therapeutically effective.
  • each treatment cycle refers to a specific period of time expressed in days or weeks that repeats on a regular schedule.
  • each treatment cycle is 15 to 30 days, such as 15 to 24 days, and preferably each treatment cycle is three weeks (ie, 21 days). In one embodiment, one treatment cycle is four weeks (ie, 28 days).
  • administration refers to the physical introduction of each active ingredient of the pharmaceutical composition of the present invention into an individual using any of a variety of methods and delivery systems known to those skilled in the art.
  • the route of administration of each active ingredient in the pharmaceutical combination of the present invention includes oral, intravenous (e.g., infusion (also known as drip) or injection), intramuscular, subcutaneous, intraperitoneal, spinal, local or other parenteral routes of administration .
  • parenteral administration refers to methods of administration other than gastrointestinal and topical administration, usually via intravenous, and without limitation includes intramuscular, intraarterial, intrathecal, intralymphatic, intralesional, intrasaccular , Intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcutaneous, intraarticular, subcapsular, subarachnoid, intraspine, epidural and intrasternal injection and infusion, and in vivo electroporation.
  • each active ingredient in the pharmaceutical combination of the present invention can be formulated into capsules, tablets, injections (including infusions or injections), syrups, sprays, lozenges, liposomes or suppositories, etc.
  • dose is the amount of a drug that induces a therapeutic effect. Unless otherwise stated, the dosage is related to the amount of the free form of the drug. If the drug is in the form of a pharmaceutically acceptable salt, the amount of the drug is increased in proportion to the amount of the drug in the free form. For example, the dosage will be stated on the product packaging or product information sheet.
  • HADC inhibitors including compounds of formula (I) formed with inorganic acids, such as hydrochloride, hydrogen Bromate, carbonate, bicarbonate, phosphate, sulfate, sulfite, nitrate, etc.
  • acid addition salts formed by HADC inhibitors including compounds of formula (I)
  • organic acids such as methyl Acid salt, acetate, malate, maleate, fumarate, tartrate, succinate, citrate, lactate, methanesulfonate, p-toluenesulfonate, 2-hydroxy Ethyl sulfonate, benzoate, salicylate, stearate, and salt formed with alkane dicarboxylic acid of the formula HOOC-(CH 2 ) n -COOH (wherein n is 0-4), etc.
  • “Pharmaceutically acceptable salts” also include base
  • pharmaceutically acceptable refers to those compounds and materials that are suitable for use in contact with human and animal tissues without excessive toxicity, irritation, allergic reactions, or other problems or complications, and commensurate with a reasonable benefit/risk ratio , Composition and/or dosage form.
  • AE adverse event
  • an adverse event may be related to the activation of the immune system in response to treatment or the expansion of immune system cells (e.g., T cells) in response to treatment.
  • Medical treatments can have one or more related AEs, and each AE can have the same or different levels of severity.
  • anti-PD-1 antibody used herein includes the anti-PD-1 antibodies described in WO2017025016, CN108473977B and WO2017133540, the entire contents of which are incorporated herein by reference.
  • the anti-PD-1 antibody is preferably the anti-PD-1 antibody D-S228P IgG4 disclosed in WO2017025016A1, which is also referred to as sintilimab in this application.
  • the numbering of the sequence used herein directly corresponds to the numbering in WO2017025016A1, and has not been renumbered.
  • HDAC inhibitor as used herein includes the compound described in Chinese application 03139760.3 (publication number CN1513839A), the entire content of which is incorporated herein by reference.
  • the HDAC inhibitor is preferably Chidamide
  • the present invention provides the aforementioned pharmaceutical combination of the present invention for preventing and/or treating the severity of at least one symptom or indication of cancer in an individual or inhibiting the growth of cancer cells.
  • the present invention provides a method of preventing or treating cancer, which comprises administering an effective amount of the pharmaceutical combination of the present invention to an individual in need.
  • the effective amount includes a preventive effective amount and a therapeutically effective amount.
  • the present invention provides the use of the aforementioned pharmaceutical combination of the present invention in the preparation of drugs for the prevention or treatment of cancer.
  • the cancer of the present invention includes solid tumors and hematological malignancies, such as non-Hodgkin’s lymphoma, hepatocellular carcinoma, ovarian cancer, endometrial cancer, lung cancer, such as non-small cell lung cancer, thymic cancer, kidney cancer, melanoma Tumors, head and neck cancer, bladder cancer, prostate cancer, breast cancer, gastrointestinal tumors, such as stomach cancer, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, colon cancer, colorectal cancer, colorectal adenocarcinoma, brain cancer, and bone cancer.
  • non-Hodgkin’s lymphoma hepatocellular carcinoma, ovarian cancer
  • lung cancer such as non-small cell lung cancer, thymic cancer, kidney cancer, melanoma Tumors, head and neck cancer, bladder cancer, prostate cancer, breast cancer, gastrointestinal tumors, such as stomach cancer, gastric adenocarcinoma, gastro
  • the cancer is preferably advanced cancer, refractory cancer and/or cancer resistant to chemotherapy, more preferably advanced solid tumor, unresectable or metastatic advanced solid tumor (confirmed by histology or cytology).
  • the cancer is preferably extranodal NK/T cell lymphoma, bowel cancer (including colorectal cancer), lung cancer (including non-small cell lung cancer).
  • the cancer is preferably late-stage recurrent or metastatic cancer (advanced malignant tumor), preferably late-stage or refractory extranodal NK/T cell lymphoma.
  • the drug combination of the present invention can be administered to individuals who have been treated with one or more previous therapies but subsequently relapsed or metastasized.
  • the drug combination of the present invention is administered to display one or more cancer-related biomarkers [e.g., programmed death ligand 1 (PD-L1), CA125, CA19-9, prostate specific antigen (PSA), lactate Individuals with elevated levels of hydrogenase, KIT, carcinoembryonic antigen, vascular endothelial growth factor (VEGF)].
  • PD-L1 programmed death ligand 1
  • PSA prostate specific antigen
  • lactate Individuals with elevated levels of hydrogenase KIT
  • carcinoembryonic antigen vascular endothelial growth factor
  • VEGF vascular endothelial growth factor
  • the anti-PD-1 antibody in the pharmaceutical combination of the present invention can be administered to an individual in need in one or more doses, where in the case of administering multiple doses, after the previous dose 1, 2, 3, 4, 5, The next dose is administered at 6, 7, 8, 9 or 10 weeks.
  • a dose of anti-PD-1 antibody may be selected from 0.1-10 mg/kg of the individual's body weight (for example, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, or 10 mg/kg).
  • each dose contains 50-500 mg of anti-PD-1 antibody, such as 50 mg, 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 450 mg, or 500 mg of anti-PD-1 antibody.
  • the HDAC inhibitor (for example, chidamide or its pharmaceutically acceptable salt) in the pharmaceutical combination of the present invention is administered approximately once a day, once every two days, once every three days, once every four days, twice a week, and weekly One time, once every two weeks for continuous administration, or two times a week for three weeks and one week off every three weeks, two times a week for two weeks and two weeks off for one week.
  • the dosage of the HDAC inhibitor is 10 to 50 mg/time, for example, 10 mg/time, 15 mg/time, 20 mg/time, 25 mg/time, 30 mg/time, 35 mg/time, 40 mg/time, 45 mg/time, or 50 mg/time.
  • the pharmaceutical combination of the present invention can be administered for at least one cycle, for example 2-12 or more treatment cycles, preferably wherein the one cycle is administered 1-2 doses of anti-PD-1 antibody, and at least The HDAC inhibitor is administered on days 1 to 10 of each cycle, preferably on days 1 to 14 or on days 1 to 21, preferably twice a week, and preferably at least 15 per cycle To 30 days, more preferably 21 days or 28 days.
  • the HDAC inhibitor in the pharmaceutical combination of the present invention is at a dose of 10 to 50 mg/time, for example, 10 mg/time, 15 mg/time, 20 mg/time, 25 mg/time, 30 mg/time, 35 mg/time, 40 mg/time, 45 mg
  • a dose of 50 mg/time or 50 mg/time is taken orally twice a week, continuously administered for 2, 3 or 4 weeks and stopped for 1 week or continuously administered during the use cycle, and the anti-PD-1 antibody is administered intravenously at 100-300 mg, such as 200 mg, Once every 3, 4, or 5 weeks, every 3, 4, or 5 weeks is a cycle.
  • the HDAC inhibitor in the pharmaceutical combination of the present invention is taken orally at a dose of 20 mg twice a week for continuous administration, and the anti-PD-1 antibody is infused intravenously at 200 mg, once every 3 weeks.
  • the HDAC inhibitor in the pharmaceutical combination of the present invention is taken orally at a dose of 25 mg twice a week for continuous administration, and the anti-PD-1 antibody is infused intravenously at 200 mg, once every 3 weeks.
  • the HDAC inhibitor in the pharmaceutical combination of the present invention is taken orally twice a week at a dose of 30 mg for continuous administration, and the anti-PD-1 antibody is infused intravenously at 200 mg, once every 3 weeks, once every 3 weeks.
  • the anti-PD-1 antibody in the pharmaceutical combination of the present invention may be administered before, at the same time, or after the start of administration of the HDAC inhibitor.
  • the anti-PD-1 antibody may be greater than 150 hours, about 150 hours, about 100 hours, about 72 hours, about 60 hours before the start of the HDAC inhibitor. , About 48 hours, about 36 hours, about 24 hours, about 12 hours, about 10 hours, about 8 hours, about 6 hours, about 4 hours, about 2 hours, about 1 hour, or about 30 minutes, about 15 minutes or Approximately 10 minutes to apply.
  • the anti-PD-1 antibody When administered after the HDAC inhibitor starts to be administered, the anti-PD-1 antibody may be about 10 minutes, about 15 minutes, about 30 minutes, about 1 hour, about 2 hours, about 4 hours, about 6 minutes after the start of administration of the HDAC inhibitor. Hours, about 8 hours, about 10 hours, about 12 hours, about 24 hours, about 36 hours, about 48 hours, about 60 hours, about 72 hours, or more than 72 hours. Administration "simultaneously" with the start of administration of the HDAC inhibitor means that the anti-PD-1 antibody is administered to the individual within less than 10 minutes (before, after, or simultaneously) of the start of administration of the HDAC inhibitor.
  • the anti-PD-1 antibody in the pharmaceutical combination of the present invention is administered after the HDAC inhibitor starts to be administered, for example, the anti-PD-1 antibody is administered about 1 hour, about 3 hours, about 6 hours after the start of the HDAC inhibitor administration. About 12 hours, about 15 hours administration.
  • the anti-PD-1 antibody in the pharmaceutical combination of the present invention is an injection, and if it is administered by intravenous infusion, the administration time may be about 15-60 minutes.
  • the administration of at least one cycle of the drug combination of the present invention results in an increased, preferably synergistically increased, ORR of the patient compared to a patient administered anti-PD-1 antibody monotherapy or HDAC inhibitor monotherapy ( Objective response rate), CRR (complete response rate), progression-free survival (PFS) or overall survival (OS).
  • the administration of at least one cycle of the drug combination of the present invention results in an increase in the patient's PFS by at least about 1 month, compared to a patient administered anti-PD-1 antibody monotherapy or HDAC inhibitor monotherapy.
  • the administration of at least one cycle of the drug combination of the present invention results in an increase in the patient's OS by at least about 1 month, compared to patients who are administered anti-PD-1 antibody monotherapy or HDAC inhibitor monotherapy.
  • the drug combination of the present invention results in an improved, preferably synergistically improved, therapeutic effect on cancer.
  • the drug combination of the present invention results in a patient's ORR (objective response rate) increased by about 10%, about 20%, About 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 100%, about 110%, about 120%, about 130%, about 140%, about 150 %, about 200%, or about 300%.
  • the drug combination of the present invention results in a patient's CRR (complete remission rate) increased by about 10%, about 20%, About 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 100%, about 110%, about 120%, about 130%, about 140%, about 150 %, about 200%, or about 300%.
  • the drug combination of the present invention results in an increase, preferably a synergistic increase in the inhibitory effect on tumor growth.
  • the drug combination of the present invention results in tumor growth being inhibited by at least about 10%, about 20%, about 30%, compared with the administration of anti-PD-1 antibody monotherapy or the administration of HDAC inhibitor monotherapy.
  • administration of the drug combination of the invention results in increased tumor regression, tumor shrinkage and/or disappearance.
  • the drug combination of the present invention prevents tumor recurrence and/or increases the duration of survival in an individual compared with an untreated individual or with a monotherapy with an anti-PD-1 antibody or a monotherapy with an HDAC inhibitor For example, increase the duration of survival by more than 15 days, more than 1 month, more than 3 months, more than 6 months, more than 12 months, more than 18 months, more than 24 months, more Within 36 months, or more than 48 months.
  • the drug combination of the present invention can increase progression-free survival or overall survival.
  • administration of the drug combination of the invention to an individual suffering from cancer results in the complete disappearance of the tumor ("complete response"). In some embodiments, administration of the drug combination of the invention to an individual suffering from cancer results in a reduction in tumor cells or tumor size by at least 30% or more (“partial response").
  • the tumor reduction can be measured by any method known in the art, such as X-ray, positron emission tomography (PET), computer tomography (CT), magnetic resonance imaging (MRI), cytology, histology, or molecular genetics analysis.
  • the pharmaceutical combination of the present invention can reduce adverse events caused by the administration of anti-PD-1 antibodies and/or HDAC inhibitors, such as hematological toxic reactions, non-hematological toxic reactions or other toxic reactions, such as pneumonia, Diarrhea, enterocolitis, renal insufficiency, skin rash, hepatitis, endocrine disease and peripheral or central neuritis, liver function abnormalities, etc.
  • hematological toxic reactions such as pneumonia, Diarrhea, enterocolitis, renal insufficiency, skin rash, hepatitis, endocrine disease and peripheral or central neuritis, liver function abnormalities, etc.
  • Another object of the present invention is to provide a kit of medicines comprising the drug combination of the present invention, preferably the kit is in the form of a single drug dosage unit.
  • kit of the present invention contains in the same package:
  • -A second container containing a pharmaceutical composition for oral administration, said pharmaceutical composition containing the HDAC inhibitor described above.
  • Sintilimab Injection Specification 10ml:100mg, Xinda Biopharmaceutical (Suzhou) Co., Ltd.
  • the age at the time of signing the ICF is ⁇ 18 years old and ⁇ 75 years old.
  • the ECOG score is 0 to 1.
  • Expected survival is greater than 3 months.
  • Coagulation function International Normalized Ratio (INR) ⁇ 1.5 times ULN; Prothrombin Time (PT), Activated Partial Thromboplastin Time (APTT) ⁇ 1.5 times ULN ( Unless the subject is receiving anticoagulant therapy, and PT and APTT are within the expected range of anticoagulant therapy at the time of screening).
  • INR International Normalized Ratio
  • PT Prothrombin Time
  • APTT Activated Partial Thromboplastin Time
  • Thyroid-stimulating hormone Thyroid-stimulating hormone (TSH) or free thyroxine (FT4) or free triiodothyronine (FT3) are all within ⁇ 10% of the normal value.
  • Subjects must pass pulmonary function tests (PFT) to confirm that forced expiratory volume (FEV1)/forced vital capacity (FVC)> 60% in the first second, unless it is caused by a large mediastinal mass caused by Hodgkin’s lymphoma This standard cannot be met; the diffusion of carbon monoxide (DLCO), FEV1 and FVC are more than 50% above the predicted value; all PFT results must be obtained within 4 weeks before the first administration of Sintilimab.
  • PFT pulmonary function tests
  • Subjects who have received anti-tumor therapy in the past should return to the Common Terminology Criteria for Adverse Events (CTCAE) v4.03 grade score ⁇ level 1 or baseline level after the toxicity of the previous treatment has returned to the evaluation criteria for common adverse events (CTCAE) Entry into the group; Grade 2 toxicity (such as thrombocytopenia, anemia, neurotoxicity, alopecia, and hearing loss) caused by previous anti-tumor therapy that is irreversible and is not expected to worsen during the study treatment period, with the consent of the investigator, you can Join the group.
  • CCAE Common Terminology Criteria for Adverse Events
  • CCAE common adverse events
  • WOBCP Women of Childbearing Potential
  • phase Ib/II clinical study This study is a phase Ib/II clinical study, divided into two parts.
  • phase Ib subjects received chidamide and sintilizumab, and the dose of chidamide was explored in this phase.
  • the initial dose of chidamide 3 dose groups (20mg, 25mg, 30mg) are set up, with 3-6 subjects in each group. Starting dose: 20 mg/time, 2 times/week, for continuous oral administration. If DLT (Dose-Limiting Toxicities) does not appear, follow the established dose escalation plan to continue the next dose level test. If there is 1 case of DLT, add 3 subjects to this dose level. When no new DLT appears, continue to the next dose level test. If there are ⁇ 2 cases of DLT, the previous dose level of this dose level is defined as MTD (Maximum Tolerated Dose).
  • Sintilimab dose 200mg/time (fixed dose), 1 time/3 weeks, intravenous infusion.
  • the administration method of the phase II study is RP2D dose (Recommended Phase II Dose, the recommended phase II clinical study dose), 2 times a week, continuous oral; Sintilizumab dose: 200 mg/time (fixed Dose), 1 time/3 weeks, intravenous infusion.
  • grade IV blood Toxicity including but not limited to the following: febrile neutropenia (ANC ⁇ 1.0 ⁇ 10 9 /L with a single body temperature >38.3°C, or continuous body temperature ⁇ 38°C for more than 1h); non-hematology of grade III or above Toxicity (excluding hair loss and electrolyte imbalance that can be corrected within 3 days); despite symptomatic treatment, nausea, vomiting or diarrhea of grade ⁇ III still occurs.
  • febrile neutropenia ANC ⁇ 1.0 ⁇ 10 9 /L with a single body temperature >38.3°C, or continuous body temperature ⁇ 38°C for more than 1h
  • non-hematology of grade III or above Toxicity excluding hair loss and electrolyte imbalance that can be corrected within 3 days
  • nausea, vomiting or diarrhea of grade ⁇ III still occurs.
  • the Sun Yat-sen University Cancer Center enrolled a total of 9 subjects.
  • the 9 subjects were divided into 3 groups, and 3 patients in each group were subjected to a study of chidamide dose climbing.
  • the three dosage levels are 20mg, 25mg, 30mg, biw (twice a week). Except for subjects 0106 and 0107 who failed to complete 6 courses of treatment due to disease progression (received 5 and 3 courses of treatment respectively) among the 9 subjects, the remaining 7 subjects all completed more than 6 courses of combined treatment. Subjects in the three dose groups did not have MTD or DLT, so the recommended dose of RP2D is 30 mg biw.
  • stage Ib 9 subjects in stage Ib can be evaluated for efficacy, of which 7 subjects (0101, 0102, 0103, 0104, 0105, 0108, 0109) obtained CR (Complete Response), and 1 subject ( 0106) After obtaining PR (Partial Response), it progressed again, and 1 subject (0107) had the effect of PD (Progressive Disease, disease progression).
  • ORR Objective Response Rate, objective response rate
  • CRR Complete Response Rate, complete response rate
  • the phase II study adopted the simon two-phase optimal design method.
  • 7 patients were enrolled. If only 4 or fewer patients are effective, the trial will be terminated. Otherwise, enter the second phase, and 21 patients will be enrolled in the second phase, that is, a total of 28 patients will be enrolled in the phase II study.
  • a Phase II clinical study was conducted. As of November 4, 2019, 11 subjects have been enrolled in the Phase II study. Subject 0117-0120 received only one course of treatment, and the efficacy has not been evaluated yet. Among them, 5 of the 0110-0116 subjects can be evaluated for efficacy, 2 cases of CR, 2 cases of SD (stable disease), and 1 case of PD.
  • NK/T cell lymphoma recurred in the right lung more than 2 years after radiotherapy and chemotherapy.
  • NK/T cell lymphoma complicated with hematopoietic syndrome, recurrence after chemotherapy and maintenance of anti-PD-1 antibody injection.
  • the patient was diagnosed with NK/T-cell lymphoma with hemophagocytic syndrome in March 2018. After treatment with HLH2004 regimen, the bloodthirsty phenomenon was corrected, and then the P-Gemox regimen was given 3 cycles of chemotherapy, and the curative effect was PR. From 2018.6-2018.8, Pembrolizumab was treated for 4 courses, and the effect was CR. Later, the treatment was stopped due to economic reasons. In April 2019, the patient went to the doctor due to "continuous high fever". On April 28, 2019, PET/CT in our hospital showed: right supraclavicular, bilateral subclavian, mediastinum, right hilum, hepatic hilum, portal space, right kidney posterior Multiple enlarged lymph nodes.
  • HDACIs Histone deacetylase inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une combinaison pharmaceutique d'un anticorps anti-PD-1 ciblant la protéine-1 de mort programmée (PD-1) et d'un inhibiteur de HDAC, ladite combinaison étant utilisée pour traiter des cancers, en particulier un lymphome à cellules NK/T extranodal. La présente invention concerne également une utilisation et un procédé d'utilisation de la combinaison pour prévenir ou traiter des cancers, en particulier un lymphome à cellules NK/T extranodal.
PCT/CN2020/138343 2019-12-23 2020-12-22 Combinaison pharmaceutique d'anticorps anti-pd-1 et d'inhibiteur d'histone désacétylase, son utilisation et son procédé d'utilisation WO2021129616A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201911337872 2019-12-23
CN201911337872.6 2019-12-23

Publications (1)

Publication Number Publication Date
WO2021129616A1 true WO2021129616A1 (fr) 2021-07-01

Family

ID=76573696

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/138343 WO2021129616A1 (fr) 2019-12-23 2020-12-22 Combinaison pharmaceutique d'anticorps anti-pd-1 et d'inhibiteur d'histone désacétylase, son utilisation et son procédé d'utilisation

Country Status (2)

Country Link
TW (1) TW202128224A (fr)
WO (1) WO2021129616A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023040804A1 (fr) * 2021-09-14 2023-03-23 信达生物制药(苏州)有限公司 Composition pharmaceutique d'anticorps anti-pd-1 et agent chimiothérapeutique et son procédé d'utilisation

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016153839A1 (fr) * 2015-03-20 2016-09-29 Merck Sharp & Dohme Corp. Combinaison d'un antagoniste de pd-1 et de vorinostat dans le traitement du cancer
CN107614011A (zh) * 2015-03-20 2018-01-19 欣达克斯制药公司 Hdac抑制剂和抗pd‑1抗体联合用于癌症的治疗
CN108473977A (zh) * 2015-08-10 2018-08-31 信达生物制药(苏州)有限公司 Pd-1抗体
CN109562177A (zh) * 2016-05-11 2019-04-02 沪亚生物国际有限责任公司 Hdac抑制剂和pd-1抑制剂的组合疗法
CN109640985A (zh) * 2016-05-11 2019-04-16 沪亚生物国际有限责任公司 Hdac抑制剂和pd-l1抑制剂的组合疗法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016153839A1 (fr) * 2015-03-20 2016-09-29 Merck Sharp & Dohme Corp. Combinaison d'un antagoniste de pd-1 et de vorinostat dans le traitement du cancer
CN107614011A (zh) * 2015-03-20 2018-01-19 欣达克斯制药公司 Hdac抑制剂和抗pd‑1抗体联合用于癌症的治疗
CN108473977A (zh) * 2015-08-10 2018-08-31 信达生物制药(苏州)有限公司 Pd-1抗体
CN109562177A (zh) * 2016-05-11 2019-04-02 沪亚生物国际有限责任公司 Hdac抑制剂和pd-1抑制剂的组合疗法
CN109640985A (zh) * 2016-05-11 2019-04-16 沪亚生物国际有限责任公司 Hdac抑制剂和pd-l1抑制剂的组合疗法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GAO, Y. ET AL.: "Anti-PD-1 Antibody (Sintilimab) Plus Histone Deacetylase Inhibitor (Chidamide) for the Treatment of Refractory or Relapsed Extrandal Natural Killer/T Cell Lymphoma, Nasal Type (r/r-ENKTL): Preliminary Results form a Prospective, Multicenter, Single-Arm, Phase Ib/II Trial (SCENT)", BLOOD, vol. 136, no. Supplement 1, 5 November 2020 (2020-11-05) - 9 December 2020 (2020-12-09), US, pages 134665, XP009528890, ISSN: 0006-4971, DOI: 10.1182/blood-2020-134665 *
GAO, YAN ET AL.: "Chinese Clinical Trial Registry", A SINGLE-ARM, MULTICENTER PHASE IB/II CLINICAL STUDY TO EVALUATE SINTILIZUMAB (SINTILIMAB, S) IN COMBINATION WITH A HISTONE DEACETYLASE INHIBITOR (CEDAR BENZONAMIDE, C) FOR THE TREATMENT OF REFRACTORY RELAPSED NATURAL KILLER CELL/T-CELL LYMPHOMA (EN), 16 January 2019 (2019-01-16), pages 1 - 6, XP009528888 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023040804A1 (fr) * 2021-09-14 2023-03-23 信达生物制药(苏州)有限公司 Composition pharmaceutique d'anticorps anti-pd-1 et agent chimiothérapeutique et son procédé d'utilisation

Also Published As

Publication number Publication date
TW202128224A (zh) 2021-08-01

Similar Documents

Publication Publication Date Title
JP6787792B2 (ja) がんの処置のための併用治療
TWI786044B (zh) 藉由投予ｐｄ-１抑制劑治療皮膚癌之方法
Chen et al. Expanding the use of arsenic trioxide: leukemias and beyond
TW201922793A (zh) Ｐｄ－１抗體和ｖｅｇｆｒ抑制劑聯合治療小細胞肺癌的用途
WO2017004092A1 (fr) Association d'un inhibiteur de l'histone désacétylase (hdac) avec un anticorps anti-pdl-1 pour le traitement du cancer
JP2023145689A (ja) Ｈｅｒ２陽性がんの処置
WO2020187152A1 (fr) Composition pharmaceutique combinée pour le traitement du cancer du poumon à petites cellules
JP2023542093A (ja) 抗腫瘍治療におけるチアウラニブと免疫チェックポイント阻害剤との組み合わせの使用
EP3042669B1 (fr) Agent antitumoral et promoteur de l'effet antitumoral
JP6359198B1 (ja) がん細胞の代謝の特異性に基づく新規抗悪性腫瘍剤
WO2020233602A1 (fr) Dérivé de quinoléine utilisé pour le traitement combiné du cancer du poumon à petites cellules
WO2021129616A1 (fr) Combinaison pharmaceutique d'anticorps anti-pd-1 et d'inhibiteur d'histone désacétylase, son utilisation et son procédé d'utilisation
WO2017176565A1 (fr) Combinaisons d'un anticorps anti-b7-h1 et d'un agoniste du peptide cxcr4 pour le traitement d'une tumeur solide
WO2021213523A1 (fr) Utilisations d'une combinaison d'anticorps anti-pd-1 et d'anticorps anti-ctla-4 dans la prévention ou le traitement du cancer
EP4327822A1 (fr) Utilisation d'un anticorps anti-pd-1 en combinaison avec une chimiothérapie de première ligne pour traiter un cancer du poumon non à petites cellules avancé
WO2021244551A1 (fr) Composition pharmaceutique combinée d'inhibiteur de kinase c-met et d'anticorps anti-pd-l1
WO2023174408A1 (fr) Combinaison pharmaceutique d'anticorps anti-tim-3 et d'anticorps anti-pd-l1
WO2021143671A1 (fr) Composition pharmaceutique d'anticorps anti-pd-1 et de dérivé de quinazoline, utilisations de la composition et son procédé d'utilisation
WO2023174278A1 (fr) Composition pharmaceutique d'anticorps anti-tim-3 et d'agent d'hypométhylation
BR112020011796A2 (pt) uso de tratamento combinado de anticorpo pd-1 e apati-nib para o tratamento de câncer de mama negativo triplo
WO2023198060A1 (fr) Association pharmaceutique d'inhibiteur de protéasome et d'anticorps anti-pd-1
WO2023072043A1 (fr) Médicament combiné pour traitement de tumeurs
WO2024048542A1 (fr) Médicament pour le traitement et/ou la prévention du cancer
CN117085124A (zh) 一种包含抗PD-L1抗体和c-Met激酶抑制剂的药物组合
WO2024051670A1 (fr) Combinaison pharmaceutique d'anticorps se liant à tim-3 et d'anticorps se liant à pd-1

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20905965

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20905965

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 20905965

Country of ref document: EP

Kind code of ref document: A1